524 related articles for article (PubMed ID: 29935546)
1. Alzheimer's disease master regulators analysis: search for potential molecular targets and drug repositioning candidates.
Vargas DM; De Bastiani MA; Zimmer ER; Klamt F
Alzheimers Res Ther; 2018 Jun; 10(1):59. PubMed ID: 29935546
[TBL] [Abstract][Full Text] [Related]
2. Parkinson's Disease Master Regulators on Substantia Nigra and Frontal Cortex and Their Use for Drug Repositioning.
Vargas DM; De Bastiani MA; Parsons RB; Klamt F
Mol Neurobiol; 2021 Apr; 58(4):1517-1534. PubMed ID: 33211252
[TBL] [Abstract][Full Text] [Related]
3. Integrated transcriptomics reveals master regulators of lung adenocarcinoma and novel repositioning of drug candidates.
De Bastiani MA; Klamt F
Cancer Med; 2019 Nov; 8(15):6717-6729. PubMed ID: 31503425
[TBL] [Abstract][Full Text] [Related]
4. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
Shoaib M; Kamal MA; Rizvi SMD
Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic Drug Repositioning for Alzheimer's Disease Based on Epigenetic Targets in Human Interactome.
Chatterjee P; Roy D; Rathi N
J Alzheimers Dis; 2018; 61(1):53-65. PubMed ID: 29199645
[TBL] [Abstract][Full Text] [Related]
6. Master Regulators Connectivity Map: A Transcription Factors-Centered Approach to Drug Repositioning.
De Bastiani MA; Pfaffenseller B; Klamt F
Front Pharmacol; 2018; 9():697. PubMed ID: 30034338
[TBL] [Abstract][Full Text] [Related]
7. Assembly and interrogation of Alzheimer's disease genetic networks reveal novel regulators of progression.
Aubry S; Shin W; Crary JF; Lefort R; Qureshi YH; Lefebvre C; Califano A; Shelanski ML
PLoS One; 2015; 10(3):e0120352. PubMed ID: 25781952
[TBL] [Abstract][Full Text] [Related]
8. A regulatory role for the insulin- and BDNF-linked RORA in the hippocampus: implications for Alzheimer's disease.
Acquaah-Mensah GK; Agu N; Khan T; Gardner A
J Alzheimers Dis; 2015; 44(3):827-38. PubMed ID: 25362032
[TBL] [Abstract][Full Text] [Related]
9. Drug Repositioning for Alzheimer's Disease Based on Systematic 'omics' Data Mining.
Zhang M; Schmitt-Ulms G; Sato C; Xi Z; Zhang Y; Zhou Y; St George-Hyslop P; Rogaeva E
PLoS One; 2016; 11(12):e0168812. PubMed ID: 28005991
[TBL] [Abstract][Full Text] [Related]
10. Condition-specific gene co-expression network mining identifies key pathways and regulators in the brain tissue of Alzheimer's disease patients.
Xiang S; Huang Z; Wang T; Han Z; Yu CY; Ni D; Huang K; Zhang J
BMC Med Genomics; 2018 Dec; 11(Suppl 6):115. PubMed ID: 30598117
[TBL] [Abstract][Full Text] [Related]
11. Single-cell network biology characterizes cell type gene regulation for drug repurposing and phenotype prediction in Alzheimer's disease.
Gupta C; Xu J; Jin T; Khullar S; Liu X; Alatkar S; Cheng F; Wang D
PLoS Comput Biol; 2022 Jul; 18(7):e1010287. PubMed ID: 35849618
[TBL] [Abstract][Full Text] [Related]
12. Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimer's disease.
Wang M; Roussos P; McKenzie A; Zhou X; Kajiwara Y; Brennand KJ; De Luca GC; Crary JF; Casaccia P; Buxbaum JD; Ehrlich M; Gandy S; Goate A; Katsel P; Schadt E; Haroutunian V; Zhang B
Genome Med; 2016 Nov; 8(1):104. PubMed ID: 27799057
[TBL] [Abstract][Full Text] [Related]
13. Articulating target-mining techniques to disinter Alzheimer's specific targets for drug repurposing.
G N S HS; Marise VLP; Rajalekshmi SG; Burri RR; Krishna Murthy TP
Comput Methods Programs Biomed; 2022 Jul; 222():106931. PubMed ID: 35724476
[TBL] [Abstract][Full Text] [Related]
14. Drug repositioning targeting glutaminase reveals drug candidates for the treatment of Alzheimer's disease patients.
Bayraktar A; Li X; Kim W; Zhang C; Turkez H; Shoaie S; Mardinoglu A
J Transl Med; 2023 May; 21(1):332. PubMed ID: 37210557
[TBL] [Abstract][Full Text] [Related]
15. Bioinformatics methods in drug repurposing for Alzheimer's disease.
Siavelis JC; Bourdakou MM; Athanasiadis EI; Spyrou GM; Nikita KS
Brief Bioinform; 2016 Mar; 17(2):322-35. PubMed ID: 26197808
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profile and functional analysis of Alzheimer's disease.
Chen F; Guan Q; Nie ZY; Jin LJ
Am J Alzheimers Dis Other Demen; 2013 Nov; 28(7):693-701. PubMed ID: 24005853
[TBL] [Abstract][Full Text] [Related]
17. Drug Repurposing for Alzheimer's Disease Based on Protein-Protein Interaction Network.
Soleimani Zakeri NS; Pashazadeh S; MotieGhader H
Biomed Res Int; 2021; 2021():1280237. PubMed ID: 34692825
[TBL] [Abstract][Full Text] [Related]
18. Drug repurposing on Alzheimer's disease through modulation of NRF2 neighborhood.
Bourdakou MM; Fernández-Ginés R; Cuadrado A; Spyrou GM
Redox Biol; 2023 Nov; 67():102881. PubMed ID: 37696195
[TBL] [Abstract][Full Text] [Related]
19. Repositioning drugs by targeting network modules: a Parkinson's disease case study.
Yue Z; Arora I; Zhang EY; Laufer V; Bridges SL; Chen JY
BMC Bioinformatics; 2017 Dec; 18(Suppl 14):532. PubMed ID: 29297292
[TBL] [Abstract][Full Text] [Related]
20. Deciphering molecular bridges: Unveiling the interplay between metabolic syndrome and Alzheimer's disease through a systems biology approach and drug repurposing.
Azizan Z; Zali H; Mirmotalebisohi SA; Bazrgar M; Ahmadiani A
PLoS One; 2024; 19(5):e0304410. PubMed ID: 38809924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
